Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Under Armour Inc Class A — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Under Armour Inc Class A trades at $6.47 (market cap $2.87B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| ACAD | UAA | |
|---|---|---|
Market Cap | $4.49B | $2.87B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $8.14 |
52-Week Low | $20.06 | $4.17 |
Enterprise Value | $3.69B | $4.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Under Armour (UAA) trades at $6.74, up 1.66% today, with a bullish technical signal from moving averages but bearish oscillators. Recent earnings show mixed results, with Q4 2026 beating expectations but Q1 2026 missing. The company faces declining revenue and negative net income margins, though international growth and a new Dodge collaboration offer potential catalysts. Cash flow remains negative, and the balance sheet shows rising debt-to-asset ratios, indicating financial strain.
The outlook is cautious due to weak North American sales and margin pressure, but analyst consensus leans hold with a $5.96 price target. Risks include consumer spending softness and execution challenges, while opportunities lie in international expansion and strategic partnerships. Investors should weigh deteriorating fundamentals against potential turnaround efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
